Medical Necessity of Omalizumab for Chronic Spontaneous Urticaria

Safety Considerations

• Omalizumab carries a small risk (0.2%) of anaphylaxis and should be administered by healthcare providers trained to recognize and treat anaphylaxis 1
• Patients should be observed for 2 hours after each of the first 3 injections and 30 minutes for subsequent injections 1, 2
• The patient should have access to an epinephrine autoinjector and be trained in its use 2

Treatment Algorithm

• Omalizumab therapy should be initiated with 300mg subcutaneously every 4 weeks, administered in a healthcare setting with anaphylaxis preparedness 1